56 results
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
28 Mar 24
Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs
8:00am
clinical research organization (CROs) and contract manufacturing organizations (CMOs), the ability of our CROs to recruit volunteers for, and to proceed
8-K
EX-99.1
COCP
Cocrystal Pharma Inc
13 Nov 23
Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:15am
) and contract manufacturing organizations (CMOs), the ability of our CROs to recruit volunteers for, and to proceed with, clinical studies, our reliance
8-K
EX-99.1
uqd794 cj373
31 Oct 23
Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344
8:00am
8-K
EX-99.1
r3z48u ua5ot6rv4gwls
16 Aug 23
Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
4:05pm
424B5
wrtew9w7hzjdgim
15 Jun 23
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
n1dahf1q
15 May 23
Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs
8:00am
8-K
EX-99.1
c18e3clyrn2
24 Apr 23
Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors
8:13am
8-K
EX-99.1
bmdl9gsdpovvpi5e3fm
10 Apr 23
Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules
8:30am
8-K
EX-99.1
ul9sj3uge4g661
26 Oct 22
Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344
8:00am
8-K
EX-99.1
tf7chh5 hpqu074
15 Aug 22
Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs
8:00am